Skip to main content
Premium Trial:

Request an Annual Quote

Danaher to Ship First Next-Gen Sequencer This Week

NEW YORK (GenomeWeb News) – Danaher Motion – Dover, a branch of US technology conglomerate Danaher that has been developing a low-cost open-source next-generation sequencer with George Church’s group at Harvard Medical School, is scheduled to ship the first commercial version of the tool later this week to the Church lab, GenomeWeb Daily News sister publication In Sequence reported yesterday.
 
In addition, the Broad Institute said it will order at least one of the instruments in order to evaluate the technology, according to the company.
 
Danaher has already received other orders and order commitments for the instrument, including an order from the Max Planck Institute of Molecular Genetics in Berlin, and plans to showcase the instrument in a hotel suite at the Advances in Genome Biology and Technology meeting on Marco Island this week.
 
The company said it will market the instrument, called the Polonator G.007, with reagent kits, flow cells, user support, and protocols and software developed by the Church lab.
 
The system currently supports paired-end sequencing with read lengths of two times 14 bases. Performance metrics such as accuracy and throughput will be available within a month, according to the Church lab.
 
According to marketing literature, the Danaher-Church team has “identified the upfront and recurring cost of second-generation sequencing as key factors inhibiting the rate of adoption, and have assiduously sought to drive these as low as possible.”
 
The instrument’s list price, $150,000, is indeed lower than those of other available next-generation sequencers — sold by Applied Biosystems, Illumina, and Roche’s 454 Life Sciences subsidiary — which list for between $430,000 and almost $600,000.
 
Researchers in the Church lab are still determining the performance of the instrument, including its throughput and accuracy, and “expect those figures within the next month,” Greg Porreca, a developer in the Church group, told In Sequence by e-mail this week.
 

 
A comprehensive version of this article appears in this week's issue of In Sequence.

The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.